Impact of Previous Abdominal Surgery and Timing of Peritoneal Metastases on Accuracy of Imaging in Predicting the Surgical PCI: A Report From the PRECINCT Study.
peritoneal MRI
peritoneal malignancy
prior surgical score
radiological PCI
radiological peritoneal cancer index
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
11 Sep 2024
11 Sep 2024
Historique:
received:
28
07
2024
accepted:
18
08
2024
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
11
9
2024
Statut:
aheadofprint
Résumé
In this report from Phase 1 of the prospective, observational, PRECINCT (Pattern of peritoneal dissemination and REsponse to systemic Chemotherapy IN Common and uncommon peritoneal Tumours) study, a correlation was performed between the radiological PCI (peritoneal cancer index; rPCI) and surgical PCI (sPCI). The impact of timing of peritoneal malignancy (PM) and previous abdominal surgery was also studied. The rPCI and sPCI were considered the 'same' if they differed by ≤ 3 points. The agreement was assessed using Bland-Altman analysis and the strength of the agreement was assessed using the concordance correlation coefficient (CCC). The extent of prior surgery was classified according to prior surgical score (PSS). In 707 (79.4%) patients, rPCI and sPCI concurred in 280 (39.6%). In the Bland-Altman analysis, < 40% patients were in the ±3 PCI points limit of acceptable difference. The average difference between the two scores was 4.5 points (95% CI- -5.16 to -3.92). The CCC- was 0.59 for the whole cohort ('moderate' concordance) and was not influenced by imaging modality, timing of PM or PSS. The rPCI underestimated sPCI by an average of 4.5 points. The role of peritoneal MRI in patients undergoing iterative procedures and the performance of imaging according to sites of recurrence need further evaluation.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
In this report from Phase 1 of the prospective, observational, PRECINCT (Pattern of peritoneal dissemination and REsponse to systemic Chemotherapy IN Common and uncommon peritoneal Tumours) study, a correlation was performed between the radiological PCI (peritoneal cancer index; rPCI) and surgical PCI (sPCI). The impact of timing of peritoneal malignancy (PM) and previous abdominal surgery was also studied.
METHODS
METHODS
The rPCI and sPCI were considered the 'same' if they differed by ≤ 3 points. The agreement was assessed using Bland-Altman analysis and the strength of the agreement was assessed using the concordance correlation coefficient (CCC). The extent of prior surgery was classified according to prior surgical score (PSS).
RESULTS
RESULTS
In 707 (79.4%) patients, rPCI and sPCI concurred in 280 (39.6%). In the Bland-Altman analysis, < 40% patients were in the ±3 PCI points limit of acceptable difference. The average difference between the two scores was 4.5 points (95% CI- -5.16 to -3.92). The CCC- was 0.59 for the whole cohort ('moderate' concordance) and was not influenced by imaging modality, timing of PM or PSS.
CONCLUSIONS
CONCLUSIONS
The rPCI underestimated sPCI by an average of 4.5 points. The role of peritoneal MRI in patients undergoing iterative procedures and the performance of imaging according to sites of recurrence need further evaluation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Alison Buseck
(A)
Basma El Khannousi
(B)
Carlos Gonzalez de Pedro
(C)
Danielle Biacchi
(D)
Marcello Deraco
(M)
Amine Souadka
(A)
Edward A Levine
(EA)
Gbadebo Adeleke
(G)
Gaurav Goswami
(G)
Isabelle Bonnefoy
(I)
Katherine Cummins Perry
(K)
Konstantinos I Votanopoulos
(KI)
Loma Parikh
(L)
Mohammad Alyami
(M)
Noah Cohen
(N)
Nazim Benzerdjeb
(N)
Nehal Shah
(N)
Nezha El Bahaoui
(N)
Nazanin Khajoueinejad
(N)
Perry Shen
(P)
Shoma Barat
(S)
Selma Khouchoua
(S)
Samantha Troob
(S)
Sakina Shaikh
(S)
Umut Sarpel
(U)
Vadim Gushchin
(V)
Vasanth Mark Samuel
(VM)
Vahan Kepenekian
(V)
Laurent Villeneuve
(L)
Sophia Stanford
(S)
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
V. Kepenekian, A. Bhatt, J. Péron, et al., “Advances in the Management of Peritoneal Malignancies,” Nature Reviews Clinical Oncology 19, no. 11 (Nov 2022): 698–718, https://doi.org/10.1038/s41571-022-00675-5.
T. R. van Oudheusden, H. J. Braam, M. D. P. Luyer, et al., “Peritoneal Cancer Patients Not Suitable for Cytoreductive Surgery and HIPEC During Explorative Surgery: Risk Factors, Treatment Options, and Prognosis,” Annals of Surgical Oncology 22, no. 4 (April 2015): 1236–1242, https://doi.org/10.1245/s10434-014-4148-x.
C. Fu, B. Zhang, T. Guo, and J. Li, “Imaging Evaluation of Peritoneal Metastasis: Current and Promising Techniques,” Korean Journal of Radiology 25, no. 1 (January 2024): 86–102, https://doi.org/10.3348/kjr.2023.0840.
I. van 't Sant, M. P. Engbersen, P. A. Bhairosing, et al., “Diagnostic Performance of Imaging for the Detection of Peritoneal Metastases: A Meta‐Analysis,” European Radiology 30, no. 6 (June 2020): 3101–3112, https://doi.org/10.1007/s00330-019-06524-x.
J. Esquivel, T. C. Chua, A. Stojadinovic, et al., “Accuracy and Clinical Relevance of Computed Tomography Scan Interpretation of Peritoneal Cancer Index in Colorectal Cancer Peritoneal Carcinomatosis: A Multi‐Institutional Study,” Journal of Surgical Oncology 102, no. 6 (2010): 565–570, https://doi.org/10.1002/jso.21601.
W. Guerrero, G. Munene, P. V. Dickson, et al., “Outcome and Factors Associated With Aborted Cytoreduction for Peritoneal Carcinomatosis,” Journal of Gastrointestinal Oncology 9, no. 4 (August 2018): 664–673, https://doi.org/10.21037/jgo.2018.04.05.
A. Laghi, D. Bellini, M. Rengo, et al., “Diagnostic Performance of Computed Tomography and Magnetic Resonance Imaging for Detecting Peritoneal Metastases: Systematic Review and Meta‐Analysis,” La Radiologia Medica 122, no. 1 (January 2017): 1–15, https://doi.org/10.1007/s11547-016-0682-x.
P. H. Sugarbaker, “Surgical Management of Carcinomatosis From Colorectal Cancer,” Clinics in Colon and Rectal Surgery 18, no. 3 (August 2005): 190–203, https://doi.org/10.1055/s-2005-916280.
C. Durot, P. Rousset, A. Thivolet, et al., “What the Radiologist Should Know About Postoperative MDCT Evaluation of a Patient Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy,” Clinical Radiology 73, no. 6 (June 2018): 517–525, https://doi.org/10.1016/j.crad.2018.02.001.
E. Bekhor, J. Carr, M. Hofstedt, et al., “The Safety of Iterative Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis: A High Volume Center Prospectively Maintained Database Analysis,” Annals of Surgical Oncology 27 (2020): 1448–1455, https://doi.org/10.1245/s10434-019-08141-w.
A. Bhatt, P. Rousset, D. Baratti, et al., “Patterns of Peritoneal Dissemination and Response to Systemic Chemotherapy in Common and Rare Peritoneal Tumours Treated By Cytoreductive Surgery: Study Protocol of a Prospective, Multicentre, Observational Study,” BMJ Open 11, no. 7 (July 2021): e046819, https://doi.org/10.1136/bmjopen-2020-046819.
S. Nougaret, E. Sadowski, Y. Lakhman, et al., “The BUMPy Road of Peritoneal Metastases in Ovarian Cancer,” Diagnostic and Interventional Imaging 103, no. 10 (October 2022): 448–459, https://doi.org/10.1016/j.diii.2022.05.003.
A. Bhatt, Y. Yonemura, N. Benzerdjeb, et al., “Pathological Assessment of Cytoreductive Surgery Specimens and Its Unexplored Prognostic Potential—A Prospective Multi‐Centric Study,” European Journal of Surgical Oncology 45, no. 12 (December 2019): 2398–2404, https://doi.org/10.1016/j.ejso.2019.07.019.
L. Villeneuve, A. Thivolet, N. Bakrin, et al., “A New Internet Tool to Report Peritoneal Malignancy Extent. Peritoneal Malignancy Stage Evaluation (PROMISE) Application,” European Journal of Surgical Oncology (EJSO) 42, no. 6 (June 2016): 877–882, https://doi.org/10.1016/j.ejso.2016.03.015.
L. Villeneuve, G. Passot, O. Glehen, et al., “The RENAPE Observational Registry: Rationale and Framework of the Rare Peritoneal Tumors French Patient Registry,” Orphanet Journal of Rare Diseases 12, no. 1 (February 2017): 37, https://doi.org/10.1186/s13023-017-0571-y.
R. C. Dresen, S. De Vuysere, F. De Keyzer, et al., “Whole‐Body Diffusion‐Weighted MRI for Operability Assessment in Patients With Colorectal Cancer and Peritoneal Metastases,” Cancer Imaging 19, no. 1 (January 7 2019): 1, https://doi.org/10.1186/s40644-018-0187-z.
K. Flicek, A. Ashfaq, C. D. Johnson, C. Menias, S. Bagaria, and N. Wasif, “Correlation of Radiologic with Surgical Peritoneal Cancer Index Scores in Patients with Pseudomyxoma Peritonei and Peritoneal Carcinomatosis: How Well Can We Predict Resectability?,” Journal of Gastrointestinal Surgery 20, no. 2 (February 2016): 307–312, https://doi.org/10.1007/s11605-015-2880-6.
R. N. Low, R. M. Barone, and J. Lucero, “Comparison of MRI and CT for Predicting the Peritoneal Cancer Index (PCI) Preoperatively in Patients Being Considered for Cytoreductive Surgical Procedures,” Annals of Surgical Oncology 22, no. 5 (May 2015): 1708–1715, https://doi.org/10.1245/s10434-014-4041-7.
I. van't Sant, W. J. van Eden, M. P. Engbersen, et al., “Diffusion‐Weighted MRI Assessment of the Peritoneal Cancer Index before Cytoreductive Surgery,” British Journal of Surgery 106, no. 4 (March 2019): 491–498, https://doi.org/10.1002/bjs.10989.
A. Bhatt, Y. Yonemura, S. Mehta, et al., “The Pathologic Peritoneal Cancer Index (PCI) Strongly Differs From the Surgical PCI in Peritoneal Metastases Arising from Various Primary Tumors,” Annals of Surgical Oncology 27, no. 8 (Augst 2020): 2985–2996, https://doi.org/10.1245/s10434-020-08234-x.
M. C. Di Donna, G. Cucinella, G. Zaccaria, et al., “Concordance of Radiological, Laparoscopic and Laparotomic Scoring to Predict Complete Cytoreduction in Women with Advanced Ovarian Cancer,” Cancers 15, no. 2 (2023): 500, https://doi.org/10.3390/cancers15020500.
A. Brandl, S. Weiss, M. von Winterfeld, et al., “Predictive Value of Peritoneal Cancer Index for Survival in Patients with Mucinous Peritoneal Malignancies Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Single Centre Experience,” International Journal of Hyperthermia 34, no. 5 (2017): 512–517.
V. Narasimhan, S. Tan, J. Kong, et al., “Prognostic Factors Influencing Survival in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Isolated Colorectal Peritoneal Metastases: A Systematic Review and Meta‐Analysis,” Colorectal Disease 22 (2020): 1482–1495, https://doi.org/10.1111/codi.15003.
S. A. S. Salo, E. Lantto, E. Robinson, et al., “Prognostic Role of Radiological Peritoneal Cancer Index in Malignant Peritoneal Mesothelioma: National Cohort Study,” Scientific Reports 10 (2020): 13257, https://doi.org/10.1038/s41598-020-70044-8.
S. L. Yang, L. H. Si, R. X. Lin, et al., “Prognostic Role of the Peritoneal Cancer Index in Ovarian Cancer Patients Who Undergo Cytoreductive Surgery: a Meta‐Analysis,” Current Problems in Cancer 47, no. 6 (December 2023): 101014, https://doi.org/10.1016/j.currproblcancer.2023.101014.